• 1
    Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey [see Comments]. JAMA 1998; 280: 156975.
  • 2
    Angell M, Kassirer JP. Alternative medicine-the risks of untested and unregulated remedies [Editorial; Comment]. N Engl J Med 1998; 339: 83941.
  • 3
    Vickers A, Zollman C. ABC of complementary medicine: herbal medicine. Br Med J 1999; 319: 10503.
  • 4
    Sutherland LR, Verhoef MJ. Why do patients seek a second opinion or alternative medicine? J Clin Gastroenterol 1994; 19: 1947.
  • 5
    Rawsthorne P, Shanahan F, Cronin NC, et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1298303.
    Direct Link:
  • 6
    Moody GA, Eaden JA, Bhakta P, et al. The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health 1998; 112: 26971.
  • 7
    Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease [see Comments]. Am J Gastroenterol 1998; 93: 697701.
    Direct Link:
  • 8
    Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986; 27: 8268.
  • 9
    Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 1996; 40: 5039.
  • 10
    Burstein HJ, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340: 17339.
  • 11
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 28796.
  • 12
    Zollman C, Vickers A. ABC of complementary medicine. Users and practitioners of complementary medicine. Br Med J 1999; 319: 8368.
  • 13
    Bodeker G. Lessons on integration from the developing world's experience. Br Med J 2001; 322: 1647.
  • 14
    Langmead L, Rampton DS. Herbal treatments in gastrointestinal and liver disease—benefits and dangers. Aliment Pharmacol Ther 2001; 15: 123952.
  • 15
    Kersnik J. Predictive characteristics of users of alternative medicine. Schweiz Med Wochenschr 2000; 130: 3904.
  • 16
    Maskarinec G, Shumay DM, Kakai H, et al. Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 2000; 6: 5318.
  • 17
    Verhoef MJ, Hagen N, Pelletier G, et al. Alternative therapy use in neurologic diseases: use in brain tumor patients. Neurology 1999; 52: 61722.
  • 18
    Sebit MB, Chandiwana SK, Latif AS, et al. Quality of life evaluation in patients with HIV-I infection: the impact of traditional medicine in Zimbabwe. Cent Afr J Med 2000; 46: 20813.
  • 19
    Petrak F, Hardt J, Clement T, et al. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol 2001; 36: 37582.
  • 20
    Hilsden RJ, Verhoef MJ. Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease. Inflammatory Bowel Diseases 1998; 4: 31823.
  • 21
    Nightingale AJ, Middleton W, Middleton SJ, et al. Evaluation of the effectiveness of a specialist nurse in the management of inflammatory bowel disease (IBD). Eur J Gastroenterol Hepatol 2000; 12: 96773.
  • 22
    Cable M. The role of patients' organizations. Int Disabil Stud 1988; 10: 1812.
  • 23
    Mayberry JF. Information booklets for patients with inflammatory bowel disease. Int Disabil Stud 1988; 10: 17980.
  • 24
    Maunder RG, de Rooy EC, Toner BB, et al. Health-related concerns of people who receive psychologic support for inflammatory bowel disease. Can J Gastroenterol 1997; 11: 6815.
  • 25
    Godber D, Mayberry JF. A preliminary report on the role of lay counseling amongst patients with inflammatory bowel disease. J R Soc Med 1988; 81: 5289.
  • 26
    Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of St. John's wort (hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 5002.